StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
THG-R.BK$7.75+0.00%
Fair $7.75+0.0%

THG-R.BK

Thonburi Healthcare Group Public Company Limited

Healthcare / Medical Care FacilitiesThailand

$7.75

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $7.75Fund rank 28/100 · Data gapFallback financials|
SA 33/D
F-Score: 7/9
Declining RevenueLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 19%

FCF escenarios

weak_data · normalized FCF $134.0M · quality 50.3/100

Data gap 28/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 21/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

33/100

D

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Revenue has declined for 3 consecutive years ROE is 0.7%, below the 5% threshold
Thesis & Journal · THG-R.BKLocal privado en este navegador · Thonburi Healthcare Group Public Company Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$13.9B

P/E

86.1x

↑

EV/EBITDA

6.5x

↓

ROE

0.7%

↑

Gross Margin

22.6%

↓

Debt/Equity

0.28

↑
52-Week Range$8
$6$10

TradingView lightweight chart

THG-R.BK price, volumen y niveles de valoración

Último $8.155Periodo -78.1%
Fair value: $7.750

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-7.7%

FCF CAGR

-38.4%

FCF margin

3.1%

FCF / Net income

2.98x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $9.10B · net income $96.2M · FCF $286.3M

2022-FY → 2025-FY

Gross margin

22.6%-7.5% pts

Operating margin

3.5%-11.8% pts

Net margin

1.1%-12.8% pts

FCF margin

3.1%-7.4% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$9.10B$9.10B$9.48B$9.84B$11.58B
Net Income$96.2M$96.2M$-1.76B$295.4M$1.60B
EBITDA$1.83B$1.83B$99.4M$2.08B$3.34B
EPS0.080.08-1.960.311.67
Gross Margin22.6%22.6%17.8%24.9%30.1%
Operating Margin3.5%3.5%-14.3%6.0%15.2%
Net Margin1.1%1.1%-18.6%3.0%13.8%
Balance Sheet
Debt/Equity0.280.281.391.081.14
Current Ratio1.231.23———
Cash Flow
Free Cash Flow$286.3M$286.3M$-336.3M$134.0M$1.22B
Returns
ROE0.7%0.7%-24.4%3.1%16.1%
Valuation
P/E86.1186.11—211.1440.36
EV/EBITDA6.506.50241.6534.6021.96
P/B0.680.682.006.636.51
Growth & Yield
Revenue Growth-4.0%-4.0%-3.7%-15.0%—
EPS Growth104.1%104.1%-734.2%-81.5%—
Dividend Yield1.7%1.7%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

104.8%

muy exigente

EPS terminal req.

$0.69

Spread vs growth

-0.8%

5Y implied EPS CAGR

59.7%

muy exigente

EPS terminal req.

$0.83

Spread vs growth

44.3%

10Y implied EPS CAGR

32.6%

muy exigente

EPS terminal req.

$1.34

Spread vs growth

71.5%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -7.1%

Total return

-7.1%

Start / end P/E

n/dx → n/dx

EPS bridge

-1.96 → 0.08

Residual

-8.8%

EPS growthn/d
Multiple reratingn/d
Dividend+1.7%
Residual / FX / buybacks / cross-term-8.8%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.